Jump to:
loading...| Preferred Name |
blinatumomab |
|
| Synonyms |
antibody MT-103 |
|
| ID |
http://purl.bioontology.org/ontology/MESH/C510808 |
|
| altLabel |
antibody MT-103 Blincyto MEDI-538 MT-103 antibody |
|
| cui |
C3864946 C4276437 C3853840 C3853839 |
|
| HM |
D018033 |
|
| Inverse of RB |
4FR53SIF3A 0 |
|
| isa | ||
| LT |
TRD |
|
| Mapped to | ||
| MDA |
20060608 |
|
| MeSH Frequency |
386 |
|
| MMR |
20191031 |
|
| notation |
C510808 |
|
| PA |
D000970 |
|
| prefLabel |
blinatumomab |
|
| SC |
1 |
|
| Scope Statement |
a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma |
|
| SRC |
Curr Opin Mol Ther 2006 Feb;8(1):62-8 |
|
| TERMUI |
T000876662 T724484 T000966286 T675543 T675544 |
|
| TH |
NLM (2020) NLM (2008) FDA SRS (2013) NLM (2015) USAN (19XX) INN (19XX) NLM (2006) |
|
| tui |
T116 T129 T121 |
Create mapping